192 related articles for article (PubMed ID: 38126343)
1. Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2.
Bulos ML; Grzelak EM; Li-Ma C; Chen E; Hull M; Johnson KA; Bollong MJ
Elife; 2023 Dec; 12():. PubMed ID: 38126343
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2.
Bulos ML; Grzelak EM; Li-Ma C; Chen E; Hull M; Johnson KA; Bollong MJ
bioRxiv; 2023 Sep; ():. PubMed ID: 37131806
[TBL] [Abstract][Full Text] [Related]
3. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
[TBL] [Abstract][Full Text] [Related]
5. Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
Kim M; Kim M; Park SJ; Lee C; Lim DS
EMBO Rep; 2016 Jan; 17(1):64-78. PubMed ID: 26598551
[TBL] [Abstract][Full Text] [Related]
6. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway.
Zhang J; Ji JY; Yu M; Overholtzer M; Smolen GA; Wang R; Brugge JS; Dyson NJ; Haber DA
Nat Cell Biol; 2009 Dec; 11(12):1444-50. PubMed ID: 19935651
[TBL] [Abstract][Full Text] [Related]
7. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1.
Fan R; Kim NG; Gumbiner BM
Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2569-74. PubMed ID: 23359693
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
10. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.
Moya IM; Halder G
Nat Rev Mol Cell Biol; 2019 Apr; 20(4):211-226. PubMed ID: 30546055
[TBL] [Abstract][Full Text] [Related]
11. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components.
Kim NG; Koh E; Chen X; Gumbiner BM
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11930-5. PubMed ID: 21730131
[TBL] [Abstract][Full Text] [Related]
13. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway.
Sun Y; Jiang T; Jia Y; Zou J; Wang X; Gu W
Cell Cycle; 2019 Oct; 18(19):2509-2523. PubMed ID: 31397203
[TBL] [Abstract][Full Text] [Related]
14. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
15. YAP-dependent proliferation by a small molecule targeting annexin A2.
Shalhout SZ; Yang PY; Grzelak EM; Nutsch K; Shao S; Zambaldo C; Iaconelli J; Ibrahim L; Stanton C; Chadwick SR; Chen E; DeRan M; Li S; Hull M; Wu X; Chatterjee AK; Shen W; Camargo FD; Schultz PG; Bollong MJ
Nat Chem Biol; 2021 Jul; 17(7):767-775. PubMed ID: 33723431
[TBL] [Abstract][Full Text] [Related]
16. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
17. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.
Kim HB; Myung SJ
BMB Rep; 2018 Mar; 51(3):119-125. PubMed ID: 29366445
[TBL] [Abstract][Full Text] [Related]
19. YAP and the Hippo pathway in cholangiocarcinoma.
Sugihara T; Isomoto H; Gores G; Smoot R
J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
[TBL] [Abstract][Full Text] [Related]
20. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version.
Zhao B; Li L; Lei Q; Guan KL
Genes Dev; 2010 May; 24(9):862-74. PubMed ID: 20439427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
